Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Ardent Health, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
21.1% vs price
Base Case (Median)
107.7% vs price
Bull Case (75th pct.)
196.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $29.94 | 189.5% | High (40%) |
| PE Comparable | $12.35 | 19.5% | Medium (25%) |
| Graham Number | $10.61 | 2.6% | Medium (40%) |
| EV/EBITDA | $13.02 | 25.9% | Medium (20%) |
| EV/FCF | $30.90 | 198.9% | Medium (20%) |
| Earnings Power Value | $33.44 | 223.4% | Medium (50%) |
Based on 6 out of 7 methods, ARDT appears undervalued at the current price of $10.34. The base case fair value of $21.48 implies 107.7% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.